Andrewk65, do you seriously believe that Janssen would maneuver to:
- Promote a Phylogica capital raising by implying a deal was in the offing;
- String along the development, once the capital was in place; with the implication that:
- They will dump the project once the development has achieved milestones.
I have no doubt that Janssen is a serious partner and that their goals and objectives are more clearly understood by applying commercial logic:
- The EET is their delivery technology for an undisclosed payload;
- We do not know if the payload is a Phylomer or if it is a Janssen development - however, it does not really matter because the delivery technology is the really valuable thing (and currently, Phylogical owns this).
Valuing Phylogica depends on a deep understanding of the value of their technologies. Price action on the stock exchange is not a factor in the objective assesment of this technology.
The traders got on board to drive the price from about 1.5c to 3.8c. The traders took their profits. I see nothing fundamental in this little side show.
PYC Price at posting:
2.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)